1-8 of 8
gaucher disease type 3
Close
Sort by
Journal Articles

HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies- Two-Year Follow-up of Multicenter Study in Singapore

Li Mei Poon, MBBS, MRCP, FRCPath, Yeh Ching Linn, MBBS, MRCP, Poh Lin Tan, Ziyi LIM, Balamurugan Vellayappan, Rajat Bhattacharyya, Ah Moy Tan, MD, Lip Kun Tan, MBBS, FRCP, FRCPath, Teck Guan Soh, Colin Phipps Diong, Wing H. Leung, MD PhD, Liang Piu Koh, MBBS, MRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 2039.
https://doi.org/10.1182/blood-2019-128014
Published: 2019
Journal Articles

Key Presenting Signs and Patient Co-Variables in Early Diagnosis of Type 3 Gaucher Disease: A Global Delphi Consensus Initiative

David J Kuter, MD DPhil, Sam Salek, PhD, Atul Mehta, MD
Journal: Blood
Blood (2016) 128 (22): 4886.
https://doi.org/10.1182/blood.V128.22.4886.4886
Published: 2016
Journal Articles

Outcome in Allo- SCT in Patients with Refrectory Acute Lymphoblastic Leukemia with Non TBI Conditioning Regimens

Ajay Sharma, MD, Velu Nair, MBBS, MD, Sataya Ranjan Das, MD, Sanjeevan Sharma, MD, Jasjit Singh, MD, Rajeev Kumar, MD, Jyoti Kotwal, MD, Jasmit Kaur, MD
Journal: Blood
Blood (2014) 124 (21): 5947.
https://doi.org/10.1182/blood.V124.21.5947.5947
Published: 2014
Journal Articles

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.

Marcos De Lima, Leandro de Padua Silva, Sergio Giralt, Krishna Komanduri, Borje S. Andersson, Chitra Hosing, Muzaffar Qazilbash, Elizabeth Shpall, Peter Thall, Weiqing Zhang, Gloria McCormick, Xuemei Wang, Uday Popat, Andres Soriano, Amin Alousi, Richard Champlin, Guillermo Garcia-Manero
Journal: Blood
Blood (2008) 112 (11): 1134.
https://doi.org/10.1182/blood.V112.11.1134.1134
Published: 2008
Journal Articles

A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.

Marcos de Lima, L. Padua, S. Giralt, C. Hosing, K. Komanduri, M. Qazilbash, E.J. Shpall, P. Thall, S. Qureshi, G. McCormick, W. Tong, U. Popat, A. Soriano, R. Champlin, G. Garcia-Manero
Journal: Blood
Blood (2007) 110 (11): 3012.
https://doi.org/10.1182/blood.V110.11.3012.3012
Published: 2007
Journal Articles

Gaucher Disease: Report about Two Cases with Mild Mutations and Severe Clinical Disease and the Response Using Enzyme Replacement Therapy.

Paulo C. Aranda, MD, Roberto Rozenberg, MD
Journal: Blood
Blood (2005) 106 (11): 3879.
https://doi.org/10.1182/blood.V106.11.3879.3879
Published: 2005
Journal Articles

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Marcos de Lima, S. Giralt, Z. Caldera, G. McCormick, M. Qazilbash, P. Anderlini, E. J. Shpall, C. Hosing, M. Donato, S. Kornblau, I. Khouri, T. Martin, D. Couriel, R. Champlin
Journal: Blood
Blood (2005) 106 (11): 841.
https://doi.org/10.1182/blood.V106.11.841.841
Published: 2005
Journal Articles

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

ZiYi Lim, Dragana Milojkovic, Laurence Pearce, Michelle Kenyon, Aloysius Ho, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti
Journal: Blood
Blood (2005) 106 (11): 1762.
https://doi.org/10.1182/blood.V106.11.1762.1762
Published: 2005